Status:
COMPLETED
Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Arthroscopy
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosed knee meniscus pathology requiring ambulatory arthroscopic meniscectomy or partial meniscectomy
- Willing to participate in study for 36 hours and come to follow-up visit 7 days post-surgery
- Exclusion criteria:
- Osteoarthritis, inflammatory arthritis, or previous fracture of index joint
- Received acetaminophen or low-dose narcotic within 8 hours of surgery
- Have received oral (4 weeks), intramuscular (2 months), intra-articular (3 months) or soft-tissue (2 months) injections of corticosteroids of the first dose of study medication or received intra-articular injections of hyaluronic acid in the index joint within 9 months of the first dose of study medication
Exclusion
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2003
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00633386
Start Date
February 1 2003
End Date
August 1 2003
Last Update
February 21 2021
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States, 85023
2
Pfizer Investigational Site
St. Petersburg, Florida, United States, 33713
3
Pfizer Investigational Site
Baltimore, Maryland, United States, 21218
4
Pfizer Investigational Site
Springfield, Massachusetts, United States, 01199